MedPath

Relationship of Cerebral Perfusion Pressure Variability to Sepsis-associated Encephalopathy

Completed
Conditions
Sepsis
Interventions
Other: no interventions
Registration Number
NCT02288715
Lead Sponsor
Kang Yan
Brief Summary

The purpose of the study is to evaluate whether variability of CPP (cerebral perfusion pressure) is related to sepsis-associated encephalopathy and outcomes of patients with sepsis.

Detailed Description

Encephalopathy is a common complication of sepsis, impaired cerebrovascular autoregulation (AR) in patients with sepsis is considered related to Sepsis-associated encephalopathy (SAE). As AR is important in stabilizing the cerebral perfusion pressure, whether greater variability of CPP is related to SAE and mortality or not remains unclear. We conduct this study to evaluate the relationship between them.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
110
Inclusion Criteria
  • clinical symptoms of sepsis, severe sepsis and septic shock
  • age over 18 years
Exclusion Criteria
  • preexisting Neurological diseases
  • traumatic brain injury
  • intracranial infectious disease
  • severe hepatic or renal dysfunction
  • ICU discharge Within 72 hours
  • pregnancy

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
SAEno interventionspatient who develop encephalopathy in the progress of sepsis
non-SAEno interventionspatient who do not develop encephalopathy in the progress of sepsis
Primary Outcome Measures
NameTimeMethod
relationship between cerebral perfusion pressure variability and sepsis-associated encephalopathycerebral perfusion pressure is assessed up to 72 hours

To estimate CPP noninvasively, we will monitor the middle cerebral artery flow velocity of patients with sepsis using transcranial Doppler ultrasound in the first 72h of their enrollment. Diagnosis of a SAE was performed using the confusion assessment method for ICU(CAM-ICU).

Secondary Outcome Measures
NameTimeMethod
Duration of mechanical ventilationAll the participants will be followed up until discharge or death, assessed up to 24 months
Time of hospital stayAll the participants will be followed up until discharge or death, assessed up to 24 months
90-day mortality rateAll the participants will be followed up until 90 days after their enrollment or death
Time of ICU stayAll the participants will be followed up until discharge or death, assessed up to 24 months
2-year quality of life of survivorsAll the participants will be followed up until 2 year after their enrollment or death

EQ-5D will be used to evaluate quality of life of survivors

1-year mortality rateAll the participants will be followed up until 1 year after their enrollment or death
2-year mortality rateAll the participants will be followed up until 2 years after their enrollment or death
1-year quality of life of survivorsAll the participants will be followed up until 1 year after their enrollment or death

EQ-5D will be used to evaluate quality of life of survivors

Trial Locations

Locations (1)

Kang Yan

🇨🇳

Chengdu, Sichuan, China

© Copyright 2025. All Rights Reserved by MedPath